Anorectal Function and Neuronal-glial-epithelial Unit in Healthy Subjects (ANOSAIN)

March 27, 2026 updated by: Rennes University Hospital

This study aims to assess the phenotype of the enteric nervous system (enteric neurons) in healthy subjects.

The enteric nervous system (ENS) is composed by enteric neurons and enteric glial cells. There is a cross-talk between ENS and the intestinal epithelial barrier (IEB). ENS and IEB together constitute the neuronal-glial-epithelial unit. This unit has a key role in gut functions. The characteristics and the phenotype of the ENS also change according to age and environmental factors. Similar study is ongoing for patients with Spina Bifida. Anorectal data and phenotype of the neuronal-glial-epithelial unit in healthy subjects is required to assess abnormality of these items in patients with neurological disease including Spina Bifida.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

16

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Rennes, France, 35033
        • Rennes University Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 65 years (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • subject aged between 18 and 65 years old age and sex matched with the first sixteen patients included and evaluated in the ANOSPIN study
  • subject who gave their written consent to participate to the present study
  • subject not included in another study
  • subject covered by social insurance system

Exclusion Criteria:

  • Pregnant or nursing women;
  • Anticoagulants therapy or coagulation disorders;
  • Past history of anal or rectal surgery
  • Crohn disease or ulcerative colitis
  • Irritable bowel syndrome according to the Rome III criteria;
  • Past history of pelvic radiotherapy
  • Pas history of rectal or anal cancer
  • Anorectal symptoms : faecal incontinence, constipation, anorectal pain, rectal prolapse;
  • CCIS >5 (faecal incontinence);
  • Kess Score >9 (constipation);
  • Colonic irrigation;
  • Use of laxatives;
  • Abnormal colonic mucosa
  • Period of exclusion;
  • Patient under guardianship or unable to give their consent;

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Other
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Other: Healthy Subjects
colonic biopsies during endoscopy and anal manometry with barostat and anal endoflip

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Number of enteric neurons per ganglion
Time Frame: data collected at the day of endoscopy
colonic biopsies will be used to study intestinal permeability, colonic inflammation and enteric nervous system
data collected at the day of endoscopy

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
density and activity of the enteric glial cells
Time Frame: data collected at the day of endoscopy
colonic biopsies will be used to study intestinal permeability, colonic inflammation and enteric nervous system
data collected at the day of endoscopy
rectal adaptation
Time Frame: data collected at the day of endoscopy
rectal adaptation is defined by a volume variation during ascending pressure (phasic distension). It will be performed with a bag connected to electronic barostat
data collected at the day of endoscopy
rectal perception
Time Frame: data collected at the day of endoscopy
It will performed by using 6-point Likert scale ranging from 0 (no sensation) to 6 (intolerable pain)
data collected at the day of endoscopy
anal distensiblity
Time Frame: data collected at the day of endoscopy
It will be performed by using ENDOFLIP
data collected at the day of endoscopy
intestinal permeability
Time Frame: data collected at the day of endoscopy
Biopsy samples collected at the time of colonoscopy will be use within a Ussing Chamber able to assess intestinal permeability. The Ussing chamber is used to measure the short-circuit current as an indicator of net ion transport taking place across an epithelium, such as gut mucosa. The measure will be performed on 2 biopsies from each patient.
data collected at the day of endoscopy
macroscopic and microscopic colonic inflammation
Time Frame: data collected at the day of endoscopy
Colonic inflammation will be assessed during the scope procedure. The physician will assess the normality of the mucosa or not in case of mucosal erythema, ulceration or a decrease of the vascular pattern. Microscopic inflammation will be assessed by the pathologist according to neutrophils infiltration in the gut, crypt abscess, crypt distortion.
data collected at the day of endoscopy

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Charlène Brochard, Md, Rennes University Hospital

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

May 5, 2017

Primary Completion (Actual)

September 28, 2017

Study Completion (Actual)

September 28, 2017

Study Registration Dates

First Submitted

February 13, 2017

First Submitted That Met QC Criteria

February 13, 2017

First Posted (Actual)

February 15, 2017

Study Record Updates

Last Update Posted (Actual)

March 30, 2026

Last Update Submitted That Met QC Criteria

March 27, 2026

Last Verified

March 1, 2026

More Information

Terms related to this study

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe